Your Guide to Peptide Research

A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties.

A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery.

A growth hormone releasing hormone analog studied for stimulating growth hormone secretion.

A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.

A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.

A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.

ADA 2026 approaches with DA-1726 earning three late-breaking posters, real-world data links GLP-1 agonists to 20-35% lower dementia risk with semaglutide showing the strongest effect, FDA compounding market attracts startup investment ahead of PCAC July meeting, sermorelin officially reinstated to Category 1, and tirzepatide MASH approval marks second incretin therapy for liver disease.

Amgen's MariTide Phase 3 MARITIME program advances across six indications with Phase 2 maintenance data showing sustained weight loss on quarterly dosing. Pfizer outlines an unprecedented 20+ obesity trial program for 2026 with ADA data imminent. AVA6103 becomes the first FAP-targeted sustained-release PDC to enter clinical trials for solid tumors. A landmark JACC meta-analysis of 99,599 patients confirms GLP-1 drugs slash cardiovascular events across all demographics. Plus: TRIUMPH-2 diabetes readout approaches as next major industry catalyst.

Retatrutide TRIUMPH-1 delivers 28.3% weight loss at 80 weeks and 30.3% at 104 weeks — the largest ever recorded in a Phase 3 obesity trial. A landmark meta-analysis of 90,000+ patients confirms GLP-1 drugs slash heart attacks, strokes, and cardiovascular death. Oral Ozempic tablets launch nationwide at $149/month. The global peptide-based health market is forecast for explosive long-term growth. Plus: AI peptide design competition unites 300 researchers, and the PCAC July countdown continues.